Novo Nordisk Q2 FY26 adjusted operating profit rises 11% to DKK 33.39 billion; net sales increase 3% to DKK 78.49 billion
Reuters2026/08/04 16:37- Novo Nordisk Q2 2026 net sales rose 2% to DKK 78.49 billion; operating profit fell 19% to DKK 27.06 billion.
- Adjusted operating profit climbed 8% to DKK 33.39 billion, excluding DKK 6.3 billion in non-cash impairment charges on pipeline intangibles.
- H1 2026 net sales increased 13% to DKK 175.31 billion; operating profit rose 20% to DKK 86.68 billion.
- Wegovy pill weekly prescriptions in the US topped 265,000 for the week ending July 17; launches expanded to the UAE in June and the UK in July.
- 2026 outlook raised: adjusted net sales growth seen at 0% to -6%, adjusted operating profit growth at 0% to -6%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
